Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 44, Issue , 2013, Pages 271-278

  Calati, Raffaella ^a   Crisafulli, Concetta ^b   Balestri, Martina ^c   Serretti, Alessandro ^c   Spina, Edoardo ^d   Calabrò, Marco ^b,d,e   Sidoti, Antonina ^b   Albani, Diego ^f   Massat, Isabelle ^g   Höfer, Peter ^h   Amital, Daniela ⁱ   Juven Wetzler, Alzbeta ⁱ   Kasper, Siegfried ^h   Zohar, Joseph ⁱ   Souery, Daniel ^j   Montgomery, Stuart ^k   Mendlewicz, Julien ^j  

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

^e IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^f MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^g HÔPITAL ROBERT DEBRÉ   (France)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ TEL AVIV UNIVERSITY   (Israel)

^j UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^k IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

more..

Author keywords

CREB1; Major depressive disorder; MAPK1; Remission; Response; Treatment resistance

Indexed keywords

ANTIDEPRESSANT AGENT; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1;

ADULT; ARTICLE; BIPOLAR DISORDER; CLINICAL FEATURE; CREB1 GENE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MAPK1 GENE; NERVE CELL PLASTICITY; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; EUROPE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MOOD DISORDERS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84876335561     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.03.005     Document Type: Article

References (90)

1. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
2. Berlim M.T., Turecki G. What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Eur Neuropsychopharmacol 2007, 17:696-707.
3. Blendy J.A. The role of CREB in depression and antidepressant treatment. Biol Psychiatry 2006, 59:1144-1150.
4. Boer U., Eglins J., Krause D., Schnell S., Schofl C., Knepel W. Enhancement by lithium of cAMP-induced CRE/CREB-directed gene transcription conferred by TORC on the CREB basic leucine zipper domain. Biochem J 2007, 408:69-77.
5. Boer U., Cierny I., Krause D., Heinrich A., Lin H., Mayr G., et al. Chronic lithium salt treatment reduces CRE/CREB-directed gene transcription and reverses its upregulation by chronic psychosocial stress in transgenic reporter gene mice. Neuropsychopharmacology 2008, 33:2407-2415.
6. Bogoyevitch M.A., Court N.W. Counting on mitogen-activated protein kinases - ERKs 3, 4, 5, 6, 7 and 8. Cell Signal 2004, 16:1345-1354.
7. Browning J.L., Patel T., Brandt P.C., Young K.A., Holcomb L.A., Hicks P.B. Clozapine and the mitogen-activated protein kinase signal transduction pathway: implications for antipsychotic actions. Biol Psychiatry 2005, 57:617-623.
8. Casu M.A., Sanna A., Spada G.P., Falzoi M., Mongeau R., Pani L. Effects of acute and chronic valproate treatments on p-CREB levels in the rat amygdala and nucleus accumbens. Brain Res 2007, 1141:15-24.
9. Catena-Dell'Osso M., Bellantuono C., Consoli G., Baroni S., Rotella F., Marazziti D. Inflammatory and neurodegenerative pathways in depression: a new avenue for antidepressant development?. Curr Med Chem 2011, 18:245-255.
10. Chen Z., Gibson T.B., Robinson F., Silvestro L., Pearson G., Xu B., et al. MAP kinases. Chem Rev 2001, 101:2449-2476.
11. CHMP Note for guidance on clinical investigation of medicinal products in the treatment of depression 2002 http://www.emea.europa.eu/pdfs/human/ewp/051897en.pdf.
12. Cohen J. Statistical power analysis for the behavioral sciences 1988, Lawrence Erlbaum Associates, Hillsdale, New Jersey.
13. Davis S., Vanhoutte P., Pages C., Caboche J., Laroche S. The MAPK/ERK cascade targets both Elk-1 and cAMP response element-binding protein to control long-term potentiation-dependent gene expression in the dentate gyrus in vivo. J Neurosci 2000, 20:4563-4572.
14. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010, 67:446-457.
15. Dowlatshahi D., MacQueen G.M., Wang J.F., Young L.T. Increased temporal cortex CREB concentrations and antidepressant treatment in major depression. Lancet 1998, 352:1754-1755.
16. Dowlatshahi D., MacQueen G.M., Wang J.F., Reiach J.S., Young L.T. G protein-coupled cyclic AMP signaling in postmortem brain of subjects with mood disorders: effects of diagnosis, suicide, and treatment at the time of death. J Neurochem 1999, 73:1121-1126.
17. Drago A., De Ronchi D., Serretti A. Incomplete coverage of candidate genes: a poorly considered bias. Curr Genomics 2007, 8:476-483.
18. Drago A., Crisafulli C., Sidoti A., Serretti A. The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes. Prog Neurobiol 2011, 94:418-460.
19. Duman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997, 54:597-606.
20. Dwivedi Y., Rizavi H.S., Zhang H., Roberts R.C., Conley R.R., Pandey G.N. Aberrant extracellular signal-regulated kinase (ERK)1/2 signalling in suicide brain: role of ERK kinase 1 (MEK1). Int J Neuropsychopharmacol 2009, 12:1337-1354.
21. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003, 53:649-659.
22. Feng P., Guan Z., Yang X., Fang J. Impairments of ERK signal transduction in the brain in a rat model of depression induced by neonatal exposure of clomipramine. Brain Res 2003, 991:195-205.
23. Flood D.G., Finn J.P., Walton K.M., Dionne C.A., Contreras P.C., Miller M.S., et al. Immunolocalization of the mitogen-activated protein kinases p42MAPK and JNK1, and their regulatory kinases MEK1 and MEK4, in adult rat central nervous system. J Comp Neurol 1998, 398:373-392.
24. Fumagalli F., Molteni R., Calabrese F., Frasca A., Racagni G., Riva M.A. Chronic fluoxetine administration inhibits extracellular signal-regulated kinase 1/2 phosphorylation in rat brain. J Neurochem 2005, 93:1551-1560.
25. Fumagalli F., Frasca A., Sparta M., Drago F., Racagni G., Riva M.A. Long-term exposure to the atypical antipsychotic olanzapine differently up-regulates extracellular signal-regulated kinases 1 and 2 phosphorylation in subcellular compartments of rat prefrontal cortex. Mol Pharmacol 2006, 69:1366-1372.
26. Golan M., Schreiber G., Avissar S. Antidepressants elevate GDNF expression and release from C(6) glioma cells in a beta-arrestin1-dependent, CREB interactive pathway. Int J Neuropsychopharmacol 2011, 14:1289-1300.
27. Gourley S.L., Wu F.J., Kiraly D.D., Ploski J.E., Kedves A.T., Duman R.S., et al. Regionally specific regulation of ERK MAP kinase in a model of antidepressant-sensitive chronic depression. Biol Psychiatry 2008, 63:353-359.
28. Gourley S.L., Wu F.J., Taylor J.R. Corticosterone regulates pERK1/2 map kinase in a chronic depression model. Ann N Y Acad Sci 2008, 1148:509-514.
29. Gupta A., Schulze T.G., Nagarajan V., Akula N., Corona W., Jiang X.Y., et al. Interaction networks of lithium and valproate molecular targets reveal a striking enrichment of apoptosis functional clusters and neurotrophin signaling. Pharmacogenomics J 2012, 12:328-341.
30. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
31. Hammonds M.D., Shim S.S. Effects of 4-week treatment with lithium and olanzapine on levels of brain-derived neurotrophic factor, B-cell CLL/lymphoma 2 and phosphorylated cyclic adenosine monophosphate response element-binding protein in the sub-regions of the hippocampus. Basic Clin Pharmacol Toxicol 2009, 105:113-119.
32. Hardingham G.E., Arnold F.J., Bading H. A calcium microdomain near NMDA receptors: on switch for ERK-dependent synapse-to-nucleus communication. Nat Neurosci 2001, 4:565-566.
33. Hisaoka K., Nishida A., Koda T., Miyata M., Zensho H., Morinobu S., et al. Antidepressant drug treatments induce glial cell line-derived neurotrophic factor (GDNF) synthesis and release in rat C6 glioblastoma cells. J Neurochem 2001, 79:25-34.
34. Hisaoka K., Maeda N., Tsuchioka M., Takebayashi M. Antidepressants induce acute CREB phosphorylation and CRE-mediated gene expression in glial cells: a possible contribution to GDNF production. Brain Res 2008, 1196:53-58.
35. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009, 71:171-186.
36. Johnson G.L., Dohlman H.G., Graves L.M. MAPK kinase kinases (MKKKs) as a target class for small-molecule inhibition to modulate signaling networks and gene expression. Curr Opin Chem Biol 2005, 9:325-331.
37. Kamei H., Nagai T., Nakano H., Togan Y., Takayanagi M., Takahashi K., et al. Repeated methamphetamine treatment impairs recognition memory through a failure of novelty-induced ERK1/2 activation in the prefrontal cortex of mice. Biol Psychiatry 2006, 59:75-84.
38. Kim S.H., Seo M.S., Jeon W.J., Yu H.S., Park H.G., Jung G.A., et al. Haloperidol regulates the phosphorylation level of the MEK-ERK-p90RSK signal pathway via protein phosphatase 2A in the rat frontal cortex. Int J Neuropsychopharmacol 2008, 11:509-517.
39. Kopnisky K.L., Chalecka-Franaszek E., Gonzalez-Zulueta M., Chuang D.M. Chronic lithium treatment antagonizes glutamate-induced decrease of phosphorylated CREB in neurons via reducing protein phosphatase 1 and increasing MEK activities. Neuroscience 2003, 116:425-435.
40. Krishnan V., Nestler E.J. Linking molecules to mood: new insight into the biology of depression. Am J Psychiatry 2010, 167:1305-1320.
41. Labasque M., Meffre J., Carrat G., Becamel C., Bockaert J., Marin P. Constitutive activity of serotonin 2C receptors at G protein-independent signaling: modulation by RNA editing and antidepressants. Mol Pharmacol 2010, 78:818-826.
42. Laifenfeld D., Karry R., Klein E., Ben-Shachar D. Alterations in cell adhesion molecule L1 and functionally related genes in major depression: a postmortem study. Biol Psychiatry 2005, 57:716-725.
43. Lee J.G., Cho H.Y., Park S.W., Seo M.K., Kim Y.H. Effects of olanzapine on brain-derived neurotrophic factor gene promoter activity in SH-SY5Y neuroblastoma cells. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:1001-1006.
44. Lemos J.C., Roth C.A., Chavkin C. Signaling events initiated by kappa opioid receptor activation: quantification and immunocolocalization using phospho-selective KOR, p38 MAPK, and K(IR) 3.1 antibodies. Methods Mol Biol 2011, 717:197-219.
45. Li B., Zhang S., Zhang H., Nu W., Cai L., Hertz L., et al. Fluoxetine-mediated 5-HT2B receptor stimulation in astrocytes causes EGF receptor transactivation and ERK phosphorylation. Psychopharmacology (Berl) 2008, 201:443-458.
46. Liang M.H., Wendland J.R., Chuang D.M. Lithium inhibits Smad3/4 transactivation via increased CREB activity induced by enhanced PKA and AKT signaling. Mol Cell Neurosci 2008, 37:440-453.
47. Lin T.Y., Yang T.T., Lu C.W., Wang S.J. Inhibition of glutamate release by bupropion in rat cerebral cortex nerve terminals. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:598-606.
48. Lu X.H., Bradley R.J., Dwyer D.S. Olanzapine produces trophic effects in vitro and stimulates phosphorylation of Akt/PKB, ERK1/2, and the mitogen-activated protein kinase p38. Brain Res 2004, 1011:58-68.
49. Maes M., Yirmyia R., Noraberg J., Brene S., Hibbeln J., Perini G., et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 2009, 24:27-53.
50. Magliaro B.C., Saldanha C.J. Clozapine protects PC-12 cells from death due to oxidative stress induced by hydrogen peroxide via a cell-type specific mechanism involving inhibition of extracellular signal-regulated kinase phosphorylation. Brain Res 2009, 1283:14-24.
51. Mai L., Jope R.S., Li X. BDNF-mediated signal transduction is modulated by GSK3beta and mood stabilizing agents. J Neurochem 2002, 82:75-83.
52. Mamdani F., Alda M., Grof P., Young L.T., Rouleau G., Turecki G. Lithium response and genetic variation in the CREB family of genes. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:500-504.
53. Mendlewicz J., Crisafulli C., Calati R., Kocabas N.A., Massat I., Linotte S., et al. Influence of COX-2 and OXTR polymorphisms on treatment outcome in treatment resistant depression. Neurosci Lett 2012, 516:85-88.
54. Mercier G., Lennon A.M., Renouf B., Dessouroux A., Ramauge M., Courtin F., et al. MAP kinase activation by fluoxetine and its relation to gene expression in cultured rat astrocytes. J Mol Neurosci 2004, 24:207-216.
55. Montminy M. Transcriptional regulation by cyclic AMP. Annu Rev Biochem 1997, 66:807-822.
56. Musazzi L., Mallei A., Tardito D., Gruber S.H., El Khoury A., Racagni G., et al. Early-life stress and antidepressant treatment involve synaptic signaling and Erk kinases in a gene-environment model of depression. J Psychiatr Res 2010, 44:511-520.
57. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia L.M. Neurobiology of depression. Neuron 2002, 34:13-25.
58. Ortiz J., Harris H.W., Guitart X., Terwilliger R.Z., Haycock J.W., Nestler E.J. Extracellular signal-regulated protein kinases (ERKs) and ERK kinase (MEK) in brain: regional distribution and regulation by chronic morphine. J Neurosci 1995, 15:1285-1297.
59. Pardo R., Andreolotti A.G., Ramos B., Picatoste F., Claro E. Opposed effects of lithium on the MEK-ERK pathway in neural cells: inhibition in astrocytes and stimulation in neurons by GSK3 independent mechanisms. J Neurochem 2003, 87:417-426.
60. Pereira A., Fink G., Sundram S. Clozapine-induced ERK1 and ERK2 signaling in prefrontal cortex is mediated by the EGF receptor. J Mol Neurosci 2009, 39:185-198.
61. Pozzi L., Hakansson K., Usiello A., Borgkvist A., Lindskog M., Greengard P., et al. Opposite regulation by typical and atypical anti-psychotics of ERK1/2, CREB and Elk-1 phosphorylation in mouse dorsal striatum. J Neurochem 2003, 86:451-459.
62. Qi X., Lin W., Li J., Pan Y., Wang W. The depressive-like behaviors are correlated with decreased phosphorylation of mitogen-activated protein kinases in rat brain following chronic forced swim stress. Behav Brain Res 2006, 175:233-240.
63. Qi X., Lin W., Li J., Li H., Wang W., Wang D., et al. Fluoxetine increases the activity of the ERK-CREB signal system and alleviates the depressive-like behavior in rats exposed to chronic forced swim stress. Neurobiol Dis 2008, 31:278-285.
64. Qi H., Mailliet F., Spedding M., Rocher C., Zhang X., Delagrange P., et al. Antidepressants reverse the attenuation of the neurotrophic MEK/MAPK cascade in frontal cortex by elevated platform stress; reversal of effects on LTP is associated with GluA1 phosphorylation. Neuropharmacology 2009, 56:37-46.
65. Raedler T.J. Inflammatory mechanisms in major depressive disorder. Curr Opin Psychiatry 2011, 24:519-525.
66. Samuels I.S., Karlo J.C., Faruzzi A.N., Pickering K., Herrup K., Sweatt J.D., et al. Deletion of ERK2 mitogen-activated protein kinase identifies its key roles in cortical neurogenesis and cognitive function. J Neurosci 2008, 28:6983-6995.
67. Schafe G.E., Atkins C.M., Swank M.W., Bauer E.P., Sweatt J.D., LeDoux J.E. Activation of ERK/MAP kinase in the amygdala is required for memory consolidation of pavlovian fear conditioning. J Neurosci 2000, 20:8177-8187.
68. Serretti A., Chiesa A., Calati R., Massat I., Linotte S., Kasper S., et al. A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. J Affect Disord 2011, 128:56-63.
69. Serretti A., Chiesa A., Calati R., Massat I., Linotte S., Kasper S., et al. A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. J Affect Disord 2012, 128:56-63.
70. Shi Y., Yuan Y., Xu Z., Pu M., Wang C., Zhang Y., et al. Genetic variation in the calcium/calmodulin-dependent protein kinase (CaMK) pathway is associated with antidepressant response in females. J Affect Disord 2012, 136:558-566.
71. Souery D., Amsterdam J., de Montigny C., Lecrubier Y., Montgomery S., Lipp O., et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 1999, 9:83-91.
72. Souery D., Papakostas G.I., Trivedi M.H. Treatment-resistant depression. J Clin Psychiatry 2006, 67(Suppl. 6):16-22.
73. Souery D., Oswald P., Massat I., Bailer U., Bollen J., Demyttenaere K., et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry 2007, 68:1062-1070.
74. StatSoft I. STATISTICA per Windows 1995, StatSoft Italia srl.
75. Sullivan P.F. Spurious genetic associations. Biol Psychiatry 2007, 61:1121-1126.
76. Sweatt J.D. The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J Neurochem 2001, 76:1-10.
77. Thase M.E. The need for clinically relevant research on treatment-resistant depression. J Clin Psychiatry 2001, 62:221-224.
78. Thase M.E., Rush A.J. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997, 58(Suppl. 13):23-29.
79. Tronson N.C., Schrick C., Fischer A., Sananbenesi F., Pages G., Pouyssegur J., et al. Regulatory mechanisms of fear extinction and depression-like behavior. Neuropsychopharmacology 2008, 33:1570-1583.
80. Uslaner J.M., Parmentier-Batteur S., Flick R.B., Surles N.O., Lam J.S., McNaughton C.H., et al. Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus. Neuropharmacology 2009, 57:531-538.
81. Vogelzangs N., Duivis H.E., Beekman A.T., Kluft C., Neuteboom J., Hoogendijk W., et al. Association of depressive disorders, depression characteristics and antidepressant medication with inflammation. Transl Psychiatry 2012, 2:e79.
82. Wang Z., Wang J., Li J., Wang X., Yao Y., Zhang X., et al. MEK/ERKs signaling is essential for lithium-induced neurite outgrowth in N2a cells. Int J Dev Neurosci 2011, 29:415-422.
83. Xia Y., Wang C.Z., Liu J., Anastasio N.C., Johnson K.M. Lithium protection of phencyclidine-induced neurotoxicity in developing brain: the role of phosphatidylinositol-3 kinase/Akt and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling pathways. J Pharmacol Exp Ther 2008, 326:838-848.
84. Xing J., Ginty D.D., Greenberg M.E. Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 1996, 273:959-963.
85. Yang B.H., Son H., Kim S.H., Nam J.H., Choi J.H., Lee J.S. Phosphorylation of ERK and CREB in cultured hippocampal neurons after haloperidol and risperidone administration. Psychiatry Clin Neurosci 2004, 58:262-267.
86. Ying S.W., Futter M., Rosenblum K., Webber M.J., Hunt S.P., Bliss T.V., et al. Brain-derived neurotrophic factor induces long-term potentiation in intact adult hippocampus: requirement for ERK activation coupled to CREB and upregulation of Arc synthesis. J Neurosci 2002, 22:1532-1540.
87. Yuan P., Zhou R., Wang Y., Li X., Li J., Chen G., et al. Altered levels of extracellular signal-regulated kinase signaling proteins in postmortem frontal cortex of individuals with mood disorders and schizophrenia. J Affect Disord 2010, 124:164-169.
88. Zhu J.J., Qin Y., Zhao M., Van Aelst L., Malinow R. Ras and Rap control AMPA receptor trafficking during synaptic plasticity. Cell 2002, 110:443-455.
89. Zunszain P.A., Hepgul N., Pariante C.M. Inflammation and depression. Curr Top Behav Neurosci 2012, 14:135-151.
90. Zusso M., Debetto P., Guidolin D., Barbierato M., Manev H., Giusti P. Fluoxetine-induced proliferation and differentiation of neural progenitor cells isolated from rat postnatal cerebellum. Biochem Pharmacol 2008, 76:391-403.